Roslyn Stella Thelingwani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1627279/publications.pdf

Version: 2024-02-01

1478505 1199594 13 152 12 6 citations g-index h-index papers 14 14 14 278 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Community burden of undiagnosed HIV infection among adolescents in Zimbabwe following primary healthcare-based provider-initiated HIV testing and counselling: A cross-sectional survey. PLoS Medicine, 2017, 14, e1002360.	8.4	33
2	In Vitro and in Silico Identification and Characterization of Thiabendazole as a Mechanism-Based Inhibitor of CYP1A2 and Simulation of Possible Pharmacokinetic Drug-Drug Interactions. Drug Metabolism and Disposition, 2009, 37, 1286-1294.	3.3	29
3	Potent inhibition of CYP1A2 by Frutinone A, an active ingredient of the broad spectrum antimicrobial herbal extract from <i>P. fruticosa </i> . Xenobiotica, 2012, 42, 989-1000.	1.1	20
4	Evaluation of Herbal Medicines: Value Addition to Traditional Medicines Through Metabolism, Pharmacokinetic and Safety Studies. Current Drug Metabolism, 2015, 15, 942-952.	1.2	16
5	The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel. European Journal of Clinical Pharmacology, 2019, 75, 1077-1087.	1.9	14
6	In vitro and in vivo human metabolism and pharmacokinetics of S―and Râ€praziquantel. Pharmacology Research and Perspectives, 2020, 8, e00618.	2.4	12
7	The effect of the Pheroid delivery system on thein vitrometabolism andin vivopharmacokinetics of artemisone. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 313-325.	3.3	5
8	Physicochemical and drug metabolism characterization of a series of 4-aminoquinoline-3-hydroxypyridin-4-one hybrid molecules with antimalarial activity. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1313-1324.	3.3	5
9	Effect of NIPRISAN® on CYP3A4 activity in vitro. European Journal of Drug Metabolism and Pharmacokinetics, 2015, 40, 115-118.	1.6	5
10	Clinically relevant enantiomer specific R―and Sâ€praziquantel pharmacokinetic drugâ€drug interactions with efavirenz and ritonavir. Pharmacology Research and Perspectives, 2021, 9, e00769.	2.4	5
11	Characterisation of artemisinin–chloroquinoline hybrids for potential metabolic liabilities. Xenobiotica, 2016, 46, 234-240.	1.1	3
12	Evaluation of 1β-Hydroxylation of Deoxycholic Acid as a Non-Invasive Urinary Biomarker of CYP3A Activity in the Assessment of Inhibition-Based Drug–Drug Interaction in Healthy Volunteers. Journal of Personalized Medicine, 2021, 11, 457.	2.5	2
13	<i>In vitro</i> screening of NIPRD-AH1 on CYP3A4 activity for plausible herb-drug interaction. International Journal of Biological and Chemical Sciences, 2015, 8, 2320.	0.2	О